Quince Therapeutics (Quince Therapeutics) YoY EBITDA Growth : -10.80% (As of Dec. 2023)

View and export this data going back to 2019. Start your Free Trial

What is Quince Therapeutics YoY EBITDA Growth?

YoY EBITDA Growth is the percentage change of EBITDA per Share over the past twelve months. Quince Therapeutics's YoY EBITDA Growth for the quarter that ended in Dec. 2023 was -10.80%.

Quince Therapeutics's EBITDA per Share for the three months ended in Dec. 2023 was $-0.20.

Quince Therapeutics YoY EBITDA Growth Historical Data

The historical data trend for Quince Therapeutics's YoY EBITDA Growth can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Quince Therapeutics YoY EBITDA Growth Chart

Quince Therapeutics Annual Data

Trend

Dec17

Dec18

Dec19

Dec20

Dec21

Dec22

Dec23

YoY EBITDA Growth

Get a 7-Day Free Trial

-284.96

-31.49

-12.40

49.72

52.69

Quince Therapeutics Quarterly Data
	Mar19	Jun19	Sep19	Dec19	Mar20	Jun20	Sep20	Dec20	Mar21	Jun21	Sep21	Dec21	Mar22	Jun22	Sep22	Dec22	Mar23	Jun23	Sep23	Dec23
YoY EBITDA Growth	Get a 7-Day Free Trial															77.52	72.93	68.88	11.05	-10.80

Quince Therapeutics YoY EBITDA Growth Calculation

YoY EBITDA Growth is the percentage change of EBITDA per Share over the past twelve months.

Quince Therapeutics's YoY EBITDA Growth for the fiscal year that ended in Dec. 2023 is calculated as:

	YoY EBITDA Growth (A: Dec. 2023 )
=	(EBITDA per Share (A: Dec. 2023 )	-	EBITDA per Share (A: Dec. 2022 ))	/	\| EBITDA per Share (A: Dec. 2022 ) \|
=	(-0.72	-	-1.522)	/	\| -1.522 \|
=	52.69 %

Quince Therapeutics's YoY EBITDA Growth for the quarter that ended in Dec. 2023 is calculated as:

	YoY EBITDA Growth (Q: Dec. 2023 )
=	(EBITDA per Share (Q: Dec. 2023 )	-	EBITDA per Share (Q: Dec. 2022 ))	/	\| EBITDA per Share (Q: Dec. 2022 )) \|
=	(-0.195	-	-0.176)	/	\| -0.176 \|
=	-10.80 %

Quince Therapeutics YoY EBITDA Growth Related Terms

Thank you for viewing the detailed overview of Quince Therapeutics's YoY EBITDA Growth provided by GuruFocus.com. Please click on the following links to see related term pages.

Quince Therapeutics (Quince Therapeutics) Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Quince Therapeutics Inc (NAS:QNCX) » Definitions » YoY EBITDA Growth

Comparable Companies

Traded in Other Exchanges

N/A

Address

601 Gateway Boulevard, Suite 1250, South San Francisco, CA, USA, 94080

Website

https://www.quincetx.com

Quince Therapeutics Inc is preclinical stage biopharmaceutical company focused on advancing innovative precision therapeutics for debilitating and rare diseases. The company discovered a broad bone-targeting drug platform designed to precisely deliver small molecules, peptides, or large molecules directly to the site of bone fracture and disease to promote rapid healing with fewer off-target safety concerns compared to non-targeted therapeutics.

Executives

David Lamond	director	C/O CORTEXYME, INC., 269 EAST GRAND AVE., SOUTH SAN FRANCISCO CA 94080
Guenter Janhofer	officer: Chief Scientific Officer	601 GATEWAY BOULEVARD, SUITE 1250, SOUTH SAN FRANCISCO CA 94080
Luca Benatti	director	C/O INTERCEPT PHARMACEUTICALS, INC., 450 WEST 15TH STREET, SUITE 505, NEW YORK NY 10011
Charles S. Ryan	officer: President	C/O APPLIED DNA SCIENCES, INC., 50 HEALTH SCIENCES DRIVE, STONY BROOK NY 11790
Dirk Thye	director, officer: Chief Executive Officer	6310 NANCY RIDGE DRIVE, SAN DIEGO CA 92121
Brendan Hannah	officer: Chief Business Officer	269 EAST GRAND AVE, SOUTH SAN FRANCISCO CA 94080
Margaret Mcloughlin	director	C/O CORTEXYME, INC., 269 EAST GRAND AVE., SOUTH SAN FRANCISCO CA 94080
Ted Monohon	officer: Chief Accounting Officer	C/O FANTEX, INC., 330 TOWNSEND ST., SUITE 234, SAN FRANCISCO CA 94107
June Bray	director	C/O BIOXCEL THERAPEUTICS, INC., 555 LONG WHARF DRIVE, NEW HAVEN CT 06511
Caryn Gordon Mcdowell	officer: Chief Legal & Adm. Officer	280 EAST GRAND AVENUE, SOUTH SAN FRANCISCO CA 94080
Karen L. Smith	officer: Chief Medical Officer	C/O JAZZ PHARMACEUTICALS PLC, 5TH FL, WATERLOO EXCHANGE, WATERLOO RD, DUBLIN L2 4 L2
Philip S Low	director	3000 KENT AVE STE A1-100, WEST LAFAYETTE IN 47906
Marwan Sabbagh	director	C/O CORTEXYME, INC., 269 EAST GRAND AVE., SOUTH SAN FRANCISCO CA 94080
Stephen S. Dominy	director, officer: Chief Scientific Officer	C/O CORTEXYME, INC., 269 EAST GRAND AVE., SOUTH SAN FRANCISCO CA 94105
Christopher P. Lowe	officer: Chief Financial Officer	2511 N LOOP 1604,, SUITE 204, SAN ANTONIO TX 78258